Literature DB >> 3276314

The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences.

J Caldwell1, A J Hutt, S Fournel-Gigleux.   

Abstract

The 2-arylpropionic acids are currently an important group of non-steroidal anti-inflammatory agents. They contain a chiral centre, and in vitro studies on inhibition of prostaglandin synthesis show that their activity resides almost exclusively in the S(+)-isomers. However, this stereoselectivity of action is not manifest in vivo, due to the thus-far-unique unidirectional metabolic inversion of the chiral centre from the inactive R(-)-isomers to the S(+)-antipodes. Available evidence strongly suggests that this reaction proceeds via the formation of the acyl CoA thioesters of the 2-arylpropionates, but the participation of enzyme(s) in the inversion process remains uncertain. Although the chiral inversion is seemingly a general feature of the fate of 2-arylpropionates, there do occur important combinations of acid and species where the reaction is not extant. The stereochemistry of the chiral centre of these acids also influences other aspects of their disposition, including the oxidative metabolism of the aryl/arylakyl moiety, glucuronidation of the -COOH group and plasma protein binding, and the importance of certain of these becomes more evident when renal function is impaired. The biological consequences of the metabolic chiral inversion and enantioselective disposition of the 2-arylpropionates have been summarized in terms of their implications for the development and use of safer and more effective drugs of this class.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276314     DOI: 10.1016/0006-2952(88)90762-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  43 in total

1.  Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines.

Authors:  L Igarza; A Soraci; N Auza; H Zeballos
Journal:  Vet Res Commun       Date:  2006-07       Impact factor: 2.459

2.  Racemic therapeutics--ethical and regulatory aspects.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  [Not Available].

Authors:  K Brune; W S Beck
Journal:  Schmerz       Date:  1992-03       Impact factor: 1.107

Review 4.  Drug chirality and its clinical significance.

Authors:  A J Hutt; S C Tan
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 5.  Preclinical and clinical development of dexketoprofen.

Authors:  D Mauleón; R Artigas; M L García; G Carganico
Journal:  Drugs       Date:  1996       Impact factor: 9.546

6.  Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes.

Authors:  Mark P Grillo; Jill C M Wait; Michelle Tadano Lohr; Smriti Khera; Leslie Z Benet
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

7.  Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations.

Authors:  G Li; G Treiber; K Maier; S Walker; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

8.  Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis.

Authors:  G Geisslinger; K P Stock; D Loew; G L Bach; K Brune
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

9.  Production of R-(-)-Ketoprofen from an Amide Compound by Comamonas acidovorans KPO-2771-4.

Authors:  K Yamamoto; K Otsubo; A Matsuo; T Hayashi; I Fujimatsu; K Komatsu
Journal:  Appl Environ Microbiol       Date:  1996-01       Impact factor: 4.792

10.  The disposition of ketoprofen enantiomers in man.

Authors:  B C Sallustio; Y J Purdie; A G Whitehead; M J Ahern; P J Meffin
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.